Canadian Cancer Trials Group Bulletins

Group Administrators Office


Recent Publications

Canadian Cancer Trials Group BR.25 -- A Phase II Study of Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) for Inoperable Stage I/II

Canadian Cancer Trials Group BR.25 was a multicentre phase II trial performed to assess a hypofractionated accelerated radiotherapy regimen for early stage non-small cell lung cancer (NSCLC) in an era when stereotactic body radiotherapy was not widely available. The trial was activated in April 2006 and enrolled 80 patients before it was closed 2 years later. The primary objective was to determine the primary tumour control rate at 2 years. Secondary endpoints included regional control rate, distant control rate, overall survival, relapse-free survival, and incidence of toxicities. The investigators conclude that conformal radiotherapy to a dose of 60 Gy in 15 fractions resulted in favorable primary tumour control and overall survival rates. Severe toxicities were uncommon with this relatively simple treatment technique.

Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright JR, Hollenhorst H, de Metz C, Campbell H, Vu TT, Karvat A, Wai ES, Ung YC, Goss G, Shepherd FA, O'Brien P, Ding K, O'Callaghan C. Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non-Small Cell Lung Cancer: Canadian Cancer Trials Group BR.25. J Natl Cancer Inst 106: 1-8, 2014.

http://jnci.oxfordjournals.org/content/106/8/dju164.full

__________________________

Canadian Cancer Trials Group CO.21 - A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (Challenge)

Abstract -- The Colon Health and Life-Long Exercise Change CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II or stage III colon cancer. The purpose of this commentary is to provide an update on the CHALLENGE trial. As of December 31, 2013, the trial had randomized 250 patients in 20 Canadian centers and 26 Australian centers, with further expansion planned. Early barriers to accrual are reported and strategies to improve accrual are discussed. Of the 250 patients randomized to date, 89% have stage III colon cancer, 56% were treated with leucovorin/5-fluorouracil/ oxaliplatin-based chemotherapy, 58% have a body mass index of at least 27.5 kg/m2, 53% are women, and the median age is 60 years. The CHALLENGE trial remains the only randomized controlled trial in colon cancer survivors that is examining the effects of an exercise program on disease-free survival.

Courneya K, Vardy J, Gill S, Jonker D, O'Brien P, Friedenreich C, Dhillon H, Wong R, Meyer R, Crawford J, Campbell K, Prapavessis H, O'Callaghan C, Turner J, Spencer L, van der Ploeg H, Tu D, Booth C. Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. Curr Colorectal Cancer Rep 10: 321-8, 2014.

http://link.springer.com/article/10.1007/s11888-014-0231-8/fulltext.html